| Identification | Back Directory | [Name]
1-[3-CYANO-4-(2,2-DIMETHYL-PROPOXY)-PHENYL]-1H-PYRAZOLE-4-CARBOXYLIC ACID | [CAS]
206884-98-2 | [Synonyms]
Y 700
Niraxostat
PIRAXOSTAT
Y 700 - Piraxostat
AETHRPHBGJAIBT-UHFFFAOYSA-N
1-[3-CYANO-4-(2,2-DIMETHYL-PROPOXY)-PHENYL]-1H-PYRAZOLE-4-CARBOXYLIC ACID
1H-PYRAZOLE-4-CARBOXYLIC ACID, 1-[3-CYANO-4-(2,2-DIMETHYLPROPOXY)PHENYL]- | [Molecular Formula]
C16H17N3O3 | [MDL Number]
MFCD09955279 | [MOL File]
206884-98-2.mol | [Molecular Weight]
299.32 |
| Chemical Properties | Back Directory | [Boiling point ]
500.5±45.0 °C(Predicted) | [density ]
1.20±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
3.68±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Niraxostat (Y-700; Piraxostat) is an orally active xanthine oxidoreductase (XOR) inhibitor used in the study of hyperuricemia and other diseases in which XOR may be involved[1]. | [in vivo]
Niraxostat (Y-700; 1 mg/kg) has high oral bioavailability (84.1%) and is almost not excreted through the kidneys. It is mainly eliminated through the liver[1].
Niraxostat (Y- 700; 1-10 mg/kg; oral; single dose) dose-dependently reduces plasma urate levels in oxonate-treated rats [1].
Niraxostat (Y-700 ; 0.3-3 mg/kg; Oral; Single dose) In normal rats, dose-dependently reduces urinary excretion of urate and allantoin while increasing excretion of hypoxanthine and xanthine [1].
Pharmacokinetic Analysis of Niraxostat (Y-700) in normal rats[1]
| Route | Dose (mg/kg) | tmax (h) | Cmax (μg/ml) | AUC0-∞ (μg/h/ml) | t1/2 (h) | | PO | 0.3 | 0.5 | 0.43 | 2.07 | 5.0 | | PO | 1 | 0.3 | 1.8 | 7.01 | 3.2 | | PO | 3 | 0.5 | 6.49 | 30.31 | 2.7 | | IV | 1 | / | 3.97 | 8.34 | 2.5 |
| [References]
[1] Fukunari A, et al. Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretion. J Pharmacol Exp Ther. 2004 Nov;311(2):519-28. DOI:10.1124/jpet.104.070433 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|